Home test tracks gut Drug's Real-World impact
NCT ID NCT05069259
Summary
This study aimed to gather real-world information on how well the drug tofacitinib works for people with moderate to severe ulcerative colitis. It involved 18 participants in Switzerland who were prescribed the drug as part of their normal care. Researchers tracked their symptoms, quality of life, and a stool-based inflammation marker over 16 weeks to understand the treatment's effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Fribourgeois de Gastroenterologie
Fribourg, Switzerland
-
Clarunis, Universitätsspital
Basel, Switzerland
-
Kantonsspital Baselland
Liestal, Switzerland
-
Kantonsspital St, Gallen
Sankt Gallen, Canton of St. Gallen, 9007, Switzerland
-
Verein IBD Study Group
Bern, CH - 3012, Switzerland
Conditions
Explore the condition pages connected to this study.